Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN NIVEN

Allopathic & Osteopathic Physicians Dermatology

NPI
1336167634
CMS profile
60481
Location
MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$30.02

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $30.02 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
LEO Pharma Inc. $15.04 1
Lilly USA, LLC $14.98 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN NIVEN

NPI 1336167634 · CMS profile ID 60481

Allopathic & Osteopathic Physicians / Dermatology

MIAMI BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN NIVEN, NPI 1336167634, CMS profile ID 60481. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN NIVEN, NPI 1336167634, CMS profile ID 60481, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336167634?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $30.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $14.9808/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657897231 CMS
LEO Pharma Inc. $15.0406/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687268449 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $30.02 2
PY2020 $5.92 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020
Generated from
OP_DTL_GNRL_PGYR2020_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $547,115.16 88
PY2024 Principal investigator $919,823.31 487
PY2023 Recipient $1,200.00 1
PY2023 Principal investigator $635,503.38 419
PY2022 Principal investigator $475,737.00 87
PY2021 Principal investigator $161,162.86 33
PY2020 Principal investigator $161,071.72 49
PY2019 Principal investigator $202,395.85 23

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

88 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
LENUS RESEARCH
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202534497
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,050.00 12/26/2025 Non-covered Recipient Entity
Interspond, Llc
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235996543
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 12/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432783
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,933.49 12/17/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GRO
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289870
Principal investigator 1 ABBVIE INC. $572.50 12/04/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202528714
Principal investigator 1 ABBVIE INC. $12,338.84 12/04/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202528716
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,327.84 12/04/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432775
Principal investigator 1 Incyte Corporation $2,500.00 12/01/2025 Non-covered Recipient Entity
INTERSPOND, LLC
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240540616
Principal investigator 1 Incyte Corporation $3,789.00 12/01/2025 Non-covered Recipient Entity
INTERSPOND, LLC
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240540640
Principal investigator 1 Incyte Corporation $2,000.00 12/01/2025 Non-covered Recipient Entity
INTERSPOND, LLC
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240540648
Principal investigator 1 Incyte Corporation $1,616.00 12/01/2025 Non-covered Recipient Entity
INTERSPOND, LLC
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240540652
Principal investigator 1 Incyte Corporation $26,000.00 12/01/2025 Non-covered Recipient Entity
INTERSPOND, LLC
A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa No dispute reported 06/30/2026 1240540660
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,885.09 12/01/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GRO
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289015
Principal investigator 1 Incyte Corporation $2,061.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540590
Principal investigator 1 Incyte Corporation $1,842.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540608
Principal investigator 1 Incyte Corporation $1,842.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540611
Principal investigator 1 Incyte Corporation $3,040.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540620
Principal investigator 1 Incyte Corporation $1,939.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540632
Principal investigator 1 Incyte Corporation $108.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540644
Principal investigator 1 Incyte Corporation $63.00 11/19/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540656
Principal investigator 1 ABBVIE INC. $1,415.00 11/05/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202521325
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,021.92 10/22/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GRO
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287253
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,449.07 10/10/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432763
Principal investigator 1 ABBVIE INC. $8,127.50 10/09/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202516237
Principal investigator 1 ABBVIE INC. $4,855.00 10/09/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202516239
Principal investigator 1 Incyte Corporation $3,040.00 10/09/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540595
Principal investigator 1 Incyte Corporation $108.00 10/09/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540599
Principal investigator 1 Incyte Corporation $63.00 10/09/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540628
Principal investigator 1 Incyte Corporation $2,061.00 10/09/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540672
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,140.65 10/08/2025 Non-covered Recipient Entity
LENUS RESEARCH & MED GRP
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190310432
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $992.00 10/08/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432750
Principal investigator 1 ABBVIE INC. $6,022.20 10/02/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202513131
Principal investigator 1 Incyte Corporation $3,789.00 10/02/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540603
Principal investigator 1 Incyte Corporation $26,000.00 10/02/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540624
Principal investigator 1 Incyte Corporation $1,616.00 10/02/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540636
Principal investigator 1 Incyte Corporation $2,000.00 10/02/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540664
Principal investigator 1 Incyte Corporation $2,500.00 10/02/2025 Non-covered Recipient Entity
INTERSPOND, LLC
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa. No dispute reported 06/30/2026 1240540668
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,358.52 09/26/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285979
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,933.77 09/17/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285616
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 09/11/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432739
Principal investigator 1 ABBVIE INC. $12,750.00 09/04/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202509744
Principal investigator 1 ABBVIE INC. $6,424.52 09/03/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202508128
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,383.68 09/03/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285033
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,991.76 08/20/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432725
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,760.23 08/15/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223284353
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,558.89 08/13/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284223
Principal investigator 1 ABBVIE INC. $7,150.00 08/06/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202503147
Principal investigator 1 ABBVIE INC. $2,893.00 08/05/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202501820
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $85.00 07/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432713
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 07/28/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,623.75 07/23/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283024
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,293.88 07/09/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282424
Principal investigator 1 ABBVIE INC. $7,150.00 07/08/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497024
Principal investigator 1 ABBVIE INC. $5,254.00 07/02/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495085
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 07/01/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432695
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,543.59 06/18/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432686
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $85.00 06/13/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432678
Principal investigator 1 ABBVIE INC. $2,361.00 06/11/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202490905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,473.45 06/04/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280708
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $26,030.76 06/04/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280728
Principal investigator 1 ABBVIE INC. $3,775.00 06/03/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202489627
Principal investigator 1 ABBVIE INC. $4,500.00 06/02/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202487291
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,663.92 05/27/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432669
Principal investigator 1 ABBVIE INC. $7,150.00 05/07/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202483221
Principal investigator 1 ABBVIE INC. $4,500.00 05/07/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up) No dispute reported 06/30/2026 1202483291
Principal investigator 1 ABBVIE INC. $9,316.10 05/07/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202483293
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $16,743.72 05/07/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279136
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,555.00 04/16/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278166
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,327.84 04/15/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432657
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,459.00 04/07/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432647
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $85.00 04/07/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432652
Principal investigator 1 ABBVIE INC. $5,124.26 04/03/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202472981
Principal investigator 1 ABBVIE INC. $3,575.00 04/03/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202473211
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,122.97 04/02/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277490
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,215.75 03/24/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432639
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 03/21/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432630
Principal investigator 1 ABBVIE INC. $9,450.52 03/07/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202460817
Principal investigator 1 ABBVIE INC. $14,300.00 03/07/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202460820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,552.88 03/07/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276149
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,327.84 03/03/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432625
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $14,447.13 03/03/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275907
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $23,093.15 02/14/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275343
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,663.92 02/07/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432617
Principal investigator 1 ABBVIE INC. $5,902.50 02/06/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447936
Principal investigator 1 ABBVIE INC. $6,416.14 02/06/2025 Non-covered Recipient Entity
LENUS RESEARCH & MEDICAL GROUP
M23-716 - A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202448069
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $24,660.22 02/05/2025 Non-covered Recipient Entity
LENUS RESEARCH AND MEDICAL GROUP
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274945
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $170.00 01/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432605
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $255.00 01/17/2025 Non-covered Recipient Entity
INTERSPOND LLC
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246432609